LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Strona główna・Stock List・Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Closed

SectorHealthcare

27.33 -0.51

Buy Sell

Overview

Share price change

24h

Current

Min

26.44

Max

27.48

Key metrics
By Trading Economics
Income	-4.6M -108M
Sales	7.1M 20M
P/E Sector Avg	3.836 66.845
EPS	-1.85
Profit margin	-541.088
Employees	539
EBITDA	-18M -120M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+43.46% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	140M 1.7B
Previous open	27.84
Previous close	27.33

News Sentiment

By Acuity

50%

154 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

28.04 / 30.06 Support & Resistance

Agios Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 lis 2025, 15:05 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Nvidia, Lowe's, Target, Semrush, MP Materials, Plug Power, Dycom, and More -- Barrons.com

Peer Comparison

Price change

Agios Pharmaceuticals Inc Forecast

Price Target

By TipRanks

43.46% upside

12 Months Forecast

Average 39.71 USD 43.46%

High 65 USD

Low 25 USD

Based on 8 Wall Street analysts offering 12 month price targets forAgios Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Agios Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

28.04 / 30.06Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

The bullish and bearish events are balanced.

Sentiment

By Acuity

154 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.